Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100
- 13 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (7), 871-884
- https://doi.org/10.1182/blood.2019003084
Abstract
Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD41 T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1-infected individuals are asymptomatic, and only 3% to 5% of carriers develop ATL. Here, we describe the contribution of aberrant DNA methylation to ATL leukemogenesis. HTLV-1-infected T-cells and their uninfected counterparts were separately isolated based on CADM1 and CD7 ex-pression status, and differentially methylated positions (DMPs) specific to HTLV-infected T cells were identified through genome-wide DNA methylation profiling. Accumulation of DNA methylation at hypermethylated DMPs correlated strongly with ATL development and progression. In addition, we identified 22 genes downregulated because of promoter hypermethylation in HTLV-1-infected T cells, including THEMIS, LAIR1, and RNF130, which negatively regulate T-cell receptor (TCR) signaling. Phosphorylation of ZAP-70, a transducer of TCR signaling, was dysregulated in HTLV-1-infected cell lines but was normalized by reex-pression of THEMIS. Therefore, we hypothesized that DNA hypermethylation contributes to growth advantages in HTLV-1-infected cells during ATL leukemogenesis. To test this idea, we investigated the anti-ATL activities of OR-1200 and OR-2100 (OR21), novel decitabine (DAC) prodrugs with enhanced oral bioavailability. Both DAC and OR21 inhibited cell growth, accompanied by global DNA hypomethylation, in xenograft tumors established by implantation of HTLV-1-infected cells. OR21 was less hematotoxic than DAC, whereas tumor growth inhibition was almost identical between the 2 compounds, making it suitable for long-term treatment of ATL patient-derived xenograft mice. Our results demonstrate that regional DNA hypermethylation is functionally important for ATL leukemogenesis and an effective therapeutic target.This publication has 48 references indexed in Scilit:
- Genetic alterations in adult T‐cell leukemia/lymphomaCancer Science, 2017
- Treatment and survival among 1594 patients with ATLBlood, 2015
- Integrated molecular analysis of adult T cell leukemia/lymphomaNature Genetics, 2015
- Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphomaThe Lancet Oncology, 2014
- Human Viral Oncogenesis: A Cancer Hallmarks AnalysisCell Host & Microbe, 2014
- Multi-Step Aberrant CpG Island Hyper-Methylation Is Associated with the Progression of Adult T–Cell Leukemia/LymphomaThe American Journal of Pathology, 2010
- Promoter methylation of the bone morphogenetic protein‐6 gene in association with adult T‐cell leukemiaInternational Journal of Cancer, 2008
- Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformationNature Reviews Cancer, 2007
- Identification of Aberrantly Methylated Genes in Association with Adult T-Cell LeukemiaCancer Research, 2004
- Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cellsBlood, 2004